If passed, the bill will add Zika to FDA’s priority review voucher program, which would help provide drug makers with an incentive to develop a vaccine for the virus. This program encourages companies to develop less cost-effective treatments for diseases that would not otherwise be attractive, and in exchange FDA reward the company by expediting the review of a more profitable drug in its pipeline.

The bill, which was passed by the Senate on March 17th, was approved by Congress on a voice vote. According to an article from Reuters, White House spokeswoman Katie Hill called this a “small step” that could encourage pharmaceutical companies to attempt to develop a treatment for Zika.